Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Deals in Depth: November 2008

Executive Summary

November 2008 dealmaking highlights: Genzyme's deal for Osiris's stem cell therapeutics Prochymal and Chondrogen topped the alliance list at a pre-commercial value of $730mm, one of the highest this year. J&J's acquisition of biomaterials company Omrix for $438mm was the highest-valued acquisition, outdoing the pharma group M&As, the leaders of which barely reached $50mm. Money invested in pharma increased slightly and again early and late VC dominated; and device financings took a nosedive, decreasing 81% from last month, and mostly comprised of debt.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts